Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Hattersley MM"'
Autor:
Collins, TA1 Teresa.Collins@astrazeneca.com, Hattersley, MM2, Yates, JWT3, Clark, E2, Mondal, M4, Mettetal, JT4
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. Jun2017, Vol. 6 Issue 6, p357-364. 8p.
Autor:
Falchook GS; Drug Development Unit, Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. Gerald.Falchook@sarahcannon.com., Reeves J; Florida Cancer Specialists South, Sarah Cannon Research Institute, Fort Meyers, FL, USA., Gandhi S; Florida Cancer Specialists South, Sarah Cannon Research Institute, St. Petersberg, FL, USA., Spigel DR; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Arrowsmith E; Tennessee Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., George DJ; Duke Cancer Institute, Durham, NC, USA., Karlix J; Sarah Cannon Research Institute, Gainesville, FL, USA., Pouliot G; Oncology R&D, AstraZeneca, Waltham, MA, USA., Hattersley MM; Oncology R&D, AstraZeneca, Waltham, MA, USA., Gangl ET; BioPharma R&D, AstraZeneca, Boston, MA, USA., James GD; Medical Statistics Consultancy Ltd, London, UK., Thompson J; Oncology R&D, AstraZeneca, Waltham, MA, USA., Russell DL; Oncology R&D, AstraZeneca, Waltham, MA, USA., Patel B; Oncology R&D, AstraZeneca, Cambridge, UK., Kumar R; Oncology R&D, AstraZeneca, Gaithersburg, MD, USA., Lim E; Medical Oncology & Hematology-LHCP, Corewell Health Medical Group, Grand Rapids, MI, USA.
Publikováno v:
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2024 Mar 02; Vol. 73 (4), pp. 72. Date of Electronic Publication: 2024 Mar 02.
Autor:
Hamilton EP; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Wang JS; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida., Oza AM; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre/University Health Network/Sinai Health Systems, Toronto, Ontario, Canada., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida., Ulahannan SV; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma., Bauer T; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Karlix JL; Sarah Cannon Development Innovations, Nashville, Tennessee., Zeron-Medina J; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fabbri G; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Marco-Casanova P; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Moorthy G; Clinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca, Boston, Massachusetts., Hattersley MM; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Littlewood GM; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Mitchell P; Early Oncology Statistics, AstraZeneca, Waltham, Massachusetts., Saeh J; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Pouliot GP; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Moore KN; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 Oct 02; Vol. 22 (10), pp. 1154-1165.
Autor:
Oien DB; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Sharma S; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Hattersley MM; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., DuPont M; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Criscione SW; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Prickett L; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Goeppert AU; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Drew L; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Yao Y; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Zhang J; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA., Chan HM; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2023 Sep 12; Vol. 7 (17), pp. 5108-5121.
Autor:
Criscione SW; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA. Steven.Criscione@astrazeneca.com., Martin MJ; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Oien DB; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Gorthi A; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA.; Department of Cell Systems & Anatomy, Greehey Children's Cancer Research Institute, University of Texas at Health San Antonio, San Antonio, TX, USA., Miragaia RJ; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Zhang J; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Chen H; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Karl DL; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Mendler K; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Markovets A; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Gagrica S; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Delpuech O; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Dry JR; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Grondine M; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Hattersley MM; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Urosevic J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Floc'h N; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Drew L; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Yao Y; Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA. yiyao1147@gmail.com., Smith PD; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK. Paul.D.Smith@astrazeneca.com.
Publikováno v:
NPJ precision oncology [NPJ Precis Oncol] 2022 Dec 27; Vol. 6 (1), pp. 95. Date of Electronic Publication: 2022 Dec 27.
Autor:
Lim EA; Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York., Bendell JC; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Falchook GS; Drug Development Unit, Sarah Cannon Research Institute at HealthONE, Denver, Colorado., Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee., Drake CG; Columbia University Herbert Irving Comprehensive Cancer Center, New York, New York., Choe JH; Duke Cancer Institute, Durham, North Carolina., George DJ; Duke Cancer Institute, Durham, North Carolina., Karlix JL; Sarah Cannon Research Institute, Gainesville, Florida., Ulahannan S; Sarah Cannon Research Institute/Oklahoma University, Oklahoma City, Oklahoma., Sachsenmeier KF; Oncology R&D, AstraZeneca, Boston, Massachusetts., Russell DL; Oncology R&D, AstraZeneca, Boston, Massachusetts., Moorthy G; Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Boston, Massachusetts., Sidders BS; Oncology Biometrics R&D, AstraZeneca, Cambridge, England, United Kingdom., Pilling EA; Oncology Biometrics R&D, AstraZeneca, Cambridge, England, United Kingdom., Chen H; Oncology R&D, AstraZeneca, Boston, Massachusetts., Hattersley MM; Oncology R&D, AstraZeneca, Boston, Massachusetts., Das M; Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Kumar R; Oncology R&D, AstraZeneca, Gaithersburg, Maryland., Pouliot GP; Oncology R&D, AstraZeneca, Boston, Massachusetts., Patel MR; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, Florida.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Nov 14; Vol. 28 (22), pp. 4871-4884.
Autor:
Bizzaro F; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy., Fuso Nerini I; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.; Laboratory of Cancer Pharmacology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Taylor MA; Early Oncology, AstraZeneca, Cambridge, UK., Anastasia A; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy., Russo M; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy., Damia G; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Guffanti F; Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy., Guana F; Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy., Ostano P; Laboratory of Cancer Genomics, Fondazione Edo ed Elvo Tempia Valenta, Biella, Italy., Minoli L; Department of Veterinary Medicine, University of Milan, Milan, Italy., Hattersley MM; Early Oncology, AstraZeneca, Boston, USA., Arnold S; Early Oncology, AstraZeneca, Cambridge, UK., Ramos-Montoya A; Early Oncology, AstraZeneca, Cambridge, UK., Williamson SC; Early Oncology, AstraZeneca, Cambridge, UK., Galbiati A; Early Oncology, AstraZeneca, Cambridge, UK., Urosevic J; Early Oncology, AstraZeneca, Cambridge, UK., Leo E; Early Oncology, AstraZeneca, Cambridge, UK., Cavallaro U; Unit of Gynecological Oncology Research, Istituto Europeo di Oncologia IRCCS, Milan, Italy., Ghilardi C; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy., Barry ST; Early Oncology, AstraZeneca, Cambridge, UK., Bani MR; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy. mariarosa.bani@marionegri.it., Giavazzi R; Laboratory of Cancer Metastasis Therapeutics, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy.
Publikováno v:
Journal of hematology & oncology [J Hematol Oncol] 2021 Nov 06; Vol. 14 (1), pp. 186. Date of Electronic Publication: 2021 Nov 06.
Autor:
Pearson AD; ACCELERATE, Europe. Electronic address: andy1pearson@btinternet.com., DuBois SG; Dana-Farber Cancer Institute/Harvard Medical School, USA., Buenger V; Coalition Against Childhood Cancer, USA., Kieran M; Bristol Myers Squibb, USA., Stegmaier K; Dana-Farber Cancer Institute/Harvard Medical School, USA., Bandopadhayay P; Dana-Farber Cancer Institute/Harvard Medical School, USA., Bennett K; AbbVie, USA., Bourdeaut F; Institut Curie, France., Brown PA; Johns Hopkins Kimmel Cancer Center, USA., Chesler L; The Institute of Cancer Research, UK., Clymer J; Dana-Farber Cancer Institute/Harvard Medical School, USA., Fox E; St Jude Children's Research Hospital, USA., French CA; Brigham and Women's Hospital/Harvard Medical School, USA., Germovsek E; Boehringer Ingelheim Pharma GmbH & Co KG, Germany., Giles FJ; Developmental Therapeutics Consortium, USA., Bender JG; Memorial Sloan Kettering Cancer Center, USA., Hattersley MM; AstraZeneca, USA., Ludwinski D; Solving Kids' Cancer, UK; Solving Kids' Cancer, USA., Luptakova K; Constellation Pharmaceuticals, USA., Maris J; Children's Hospital of Philadelphia, USA., McDonough J; The Andrew McDonough B+ Foundation, USA., Nikolova Z; Celgene International, a Bristol Myers Squibb Company, Switzerland., Smith M; National Cancer Institute, USA., Tsiatis AC; Plexxikon, USA., Vibhakar R; University of Colorado and Children's Hospital Colorado, USA., Weiner S; Children's Cancer Cause, USA., Yi JS; Texas Children's Hospital/Baylor College of Medicine, USA., Zheng F; Incyte, USA., Vassal G; ACCELERATE, Europe; Gustave Roussy, France.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Mar; Vol. 146, pp. 115-124. Date of Electronic Publication: 2021 Feb 16.
Autor:
Yang B; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA. Electronic address: byang@kymeratx.com., Hird AW; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Bodnarchuk MS; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Building 310, Cambridge Science Park, Milton Road, Cambridge, UK., Zheng X; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Dakin L; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Su Q; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Daly K; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Godin R; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Hattersley MM; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Brassil P; Drug Metabolism and Pharmacokinetics, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Redmond S; Oncology Safety, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., John Russell D; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA., Janetka JW; Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, USA.
Publikováno v:
Bioorganic & medicinal chemistry [Bioorg Med Chem] 2020 Jan 15; Vol. 28 (2), pp. 115227. Date of Electronic Publication: 2019 Dec 11.
Autor:
Adeegbe DO; Laura & Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York. Kwok-Kin.Wong@nyumc.org Dennis.Adeegbe@nyumc.org., Liu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Hattersley MM; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Bowden M; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Zhou CW; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Li S; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China., Vlahos R; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Grondine M; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Dolgalev I; Applied Bioinformatics Laboratories and Department of Pathology, New York University School of Medicine, New York, New York., Ivanova EV; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Quinn MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Gao P; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Hammerman PS; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Bradner JE; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Diehl JA; Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina., Rustgi AK; Division of Gastroenterology, Departments of Medicine and Genetics, Abramson Cancer Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania., Bass AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Tsirigos A; Applied Bioinformatics Laboratories and Department of Pathology, New York University School of Medicine, New York, New York., Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Chen H; Oncology Innovative Medicines Unit, AstraZeneca R&D Boston, Waltham, Massachusetts., Wong KK; Laura & Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, New York. Kwok-Kin.Wong@nyumc.org Dennis.Adeegbe@nyumc.org.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2018 Oct; Vol. 6 (10), pp. 1234-1245. Date of Electronic Publication: 2018 Aug 07.